Sareum's FLT3+Aurora Kinase programme targets Acute Myeloid Leukaemia (AML) and other blood cancers. The programme is currently undergoing preclinical studies. We plan to use the data from these studies to prepare an application to undertake clinical studies in cancer patients.
In disease models of AML, the candidate molecule demonstrates greater than 98% tumour inhibition. The molecule also has potent cell-killing activity against other cancers, particularly Acute Lymphoblastic Leukaemia (ALL) and other blood cancers.
Mutations to FLT3 kinase are the most common genetic defects associated with AML. Patients with AML that carry these mutations have significantly poorer outcomes.
Aurora kinase activity is required for cell division and is often found to be over activated in AML and other cancers.
It is thought that a combination of FLT3 and Aurora kinase inhibition will be able to target AML whilst being less susceptible to the drug resistance observed in the clinic with FLT3 specific inhibitors such as Quizartinib.
Find out more by getting in touch at